Scientists pinpoint a protein critical to the function of the Ebola virus, offering hope of novel drugs to stop it

December 03, 2000

Scientists at the University of Pennsylvania's School of Veterinary Medicine have identified a sequence of just four amino acids in a key viral protein that may be critical to the spread of the Ebola virus. Their findings, reported in the Dec. 5 issue of the Proceedings of the National Academy of Sciences, offer the promise of future treatments for Ebola outbreaks that now prove fatal for up to 90 percent of victims.

Ebola hemorrhagic fever is one of the most dangerous and ghastly viral diseases known to humans, but much about the underlying virus continues to elude researchers, said lead author Ronald N. Harty, Ph.D. Like all viruses, Ebola requires a host in order to replicate, invading host cells and using them as factories to crank out countless copies of its own genetic material.

Harty's work indicates that after this newly created RNA is packaged into viral protein coats, the newborn viruses rely on the little-known VP40 protein to traverse the cell's membrane, exiting the cell by simply budding off from it. These viruses proceed to infect other host cells until the cumulative effect of this explosive viral proliferation overwhelms the body.

The function of VP40, found directly under the virus's external coat, had previously been unknown. Harty worked with the isolated protein and single mammalian cells to discover that a short segment of VP40 appears to be what enables Ebola to slip out of host cells.

"This new understanding of the role VP40 plays in Ebola's replication cycle could be a critical first step in the development of new antiviral drugs to combat Ebola," said Harty, an assistant professor of pathobiology. "Now that we've identified this vital region of this key protein, we may have a target for new Ebola-fighting medications."

Because Ebola hemorrhagic fever occurs only in relatively small, sporadic outbreaks, Harty said antiviral drugs represent a logical approach to controlling the disease. There is currently no specific treatment other than the administration of intravenous fluids to combat severe dehydration.

Harty's findings implicate a proline-rich sequence of amino acids within VP40 as the key to its ability to bud efficiently from cell membranes. This segment of the protein - dubbed a PPxY motif because of its signature sequence of two prolines (P) and a tyrosine (Y) separated by any single amino acid - interacts physically and functionally with cell enzymes known as ubiq-uitin ligases. Such a virus-host interaction is thought to be crucial for the virus to escape from the cell.

One of just seven proteins produced by Ebola, VP40 was significantly impaired in its ability to exit mammalian cells by even the slightest mutations affecting the PPxY motif, Harty found.

"Motifs similar or identical to PPxY are also common in other viruses, including HIV and the virus responsible for rabies," Harty said. "In each case, they function in virus release from infected cells, and they may carry out this function by mediating interactions with host cell proteins."

Harty was joined in the research by Melissa E. Brown and Felicia P. Hayes at Penn and by Guangli Wang and Jon Huibregtse at the University of Texas at Austin. The work was funded by the University of Pennsylvania Research Foundation.
About Ebola hemorrhagic fever
World Health Organization statistics indicate that Ebola hemorrhagic fever has killed 793 of 1,100 known victims since it was first identified in Sudan and Zaire in 1976. Ebola is believed to originate in the jungles of Africa and Asia, although it's not known where, how or in what carrier species the virus lies dormant between outbreaks.

Ebola is transmitted through close contact with bodily fluids, such as mucus, saliva and blood. Ebola hemorrhagic fever can take days or weeks to incubate, manifesting itself only with the sudden onset of fever, weakness, muscle pain, headache and sore throat, followed by vomiting, diarrhea, rashes and reduced kidney and liver functions. Later, victims start to hemorrhage and bleed through the nose, mouth, eyes and other orifices. Blood and other bodily fluids also begin seeping through the skin, producing painful blisters.

The last major Ebola outbreak was in 1995 in Zaire, with as many as 300 lives lost; the most recent outbreak, in Uganda, killed more than 100 people two months ago. Because the virus typically kills its victims faster than it can spread, outbreaks have usually been extinguished before spreading very far.

University of Pennsylvania

Related Ebola Articles from Brightsurf:

Targeting the shell of the Ebola virus
As the world grapples with COVID-19, the Ebola virus is again raging.

Why doesn't Ebola cause disease in bats, as it does in people?
A new study by researchers from The University of Texas Medical Branch at Galveston uncovered new information on why the Ebola virus can live within bats without causing them harm, while the same virus wreaks deadly havoc to people.

Ebola transmission risks would be taken more seriously with ground-up interventions
A study led by the University of Kent's Durrell Institute of Conservation and Ecology (DICE) has found significant differences in disease risk perception and channels of information about Ebola virus disease (EVD) in rural areas and urban centres of Guinea, West Africa.

US inroads to better Ebola vaccine
As the world focuses on finding a COVID-19 vaccine, research continues on other potentially catastrophic pandemic diseases, including Ebola and Marburg viruses.

Ebola antibodies at work
Scientists in Israel and Germany show, on the molecular level, how an experimental vaccine offers long-term protection against the disease.

Half of Ebola outbreaks undetected
An estimated half of Ebola virus disease outbreaks have gone undetected since it was discovered in 1976, according to research published in PLOS Neglected Tropical Diseases.

Protecting those on the frontline from Ebola
Online training developed at the Medical University of South Carolina (MUSC) increased the knowledge of health care workers about effective prevention of Ebola up to 19 percent and reduced critical errors to 2.3 percent in a small MUSC cohort.

Another piece of Ebola virus puzzle identified
A team of researchers have discovered the interaction between an Ebola virus protein and a protein in human cells that may be an important key to unlocking the pathway of replication of the killer disease in human hosts.

How the human immune system protects against Ebola
'The current approach for treatment of filovirus infections with antibody cocktails tested in animal models utilizes the principle of targeting of non-overlapping epitopes.

How to slow down Ebola
The phylogenetic tree of the 2013-2016 Ebola epidemic doesn't just tell us how the Ebola virus was able to evolve: it also reveals which events and preventive measures accelerated or slowed down its spread.

Read More: Ebola News and Ebola Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to